Reading Published Dose Ranges Correctly Retatrutides Phase 3 TRIUMPH-1 trial, with topline results reported by Eli Lilly in May 2026, evaluated three target doses 4mg, 9mg, and 12mg weekly with all arms starting at 2mg and escalating in steps every four weeks (2mg 4mg 6mg 9mg 12mg, depending on target arm) rather than starting at the target dose directly
Considerations: Longer downtime and higher cost
Patience during escalation is critical
Wharton, S., Davies, M., Dicker, D., Lingvay, I., Mosenzon, O., Rubino, D
Discovery and evaluation of DA-302168S as an efficacious oral small-molecule glucagon-like peptide-1 receptor agonist